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Abstract: Surgical management of glaucoma offers a means of effective disease control. 
A gel stent that facilitates drainage to the subconjunctival space offers intraocular pressure (IOP) 
reduction similar to traditional glaucoma filtering surgeries in a less invasive manner. However, 
like all subconjunctival filtering procedures that result in a bleb, fibrosis can present as a cause of 
elevated IOP. The following proposed techniques and recommendations for managing elevated 
IOP due to bleb fibrosis after gel stent implantation are based on the clinical experience of the 
authors. The goal of this paper is to improve outcomes following gel stent surgery by providing 
guidance on assessment of bleb function and strategies for bleb enhancement.
Keywords: glaucoma gel stent, bleb management, bleb fibrosis, glaucoma surgery, glaucoma 
filtering surgery, bleb needling
Introduction
The glaucoma treatment landscape has changed significantly in the last few years 
with the introduction of a variety of new surgical procedures. While the use of the 
subconjunctival space to drain aqueous humor from the anterior chamber has been a 
cornerstone of glaucoma surgery for more than a century,1 traditional bleb-forming 
procedures, such as trabeculectomy, are associated with significant risks. The XEN 
gel stent (Allergan PLC, Irvine, CA, USA) seeks to achieve outcomes similar to a 
trabeculectomy with higher predictability, faster recovery, less tissue manipulation, 
and fewer sight-threatening complications.2,3
The gel stent is a hydrophilic tube 6 mm long with an inner diameter of ~45 µm 
that drains aqueous from the anterior chamber to the subconjunctival space. The device 
is implanted ab interno to minimize tissue disruption and is designed to restrict the 
flow of aqueous in order to minimize the risk of hypotony.4 General recommendation 
for preoperative assessment, surgical technique, and postoperative follow-up has been 
published.5 However, very few guidelines on management options for bleb failure 
are available.
Wound healing
The natural wound healing process after filtration surgery may result in decreased 
aqueous outflow due to subconjunctival and episcleral fibrosis. Furthermore, the mere 
presence of fluid or a pressure head in the subconjunctival space stimulates a cellular 
reaction that reduces tissue porosity.6 The aqueous in glaucoma patients and others 
with elevated IOP contains higher levels of inflammatory cytokines PGE2 and TGFβ, 
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substances that play a key role in inflammation and postop-
erative fibrosis.7,8 As inflammation and fibrosis have been 
primary causes of failure in filtering surgeries,9 understanding 
the wound healing process is advantageous to preventing 
filtration failure. The first stage of wound healing is the 
inflammatory phase, of which hemostasis is an integral part. 
Blood clotting results in the secretion of pro-inflammatory 
and proangiogenic cytokines, thereby impacting the diameter 
and permeability of the conjunctival and episcleral vessels. 
In addition, the trauma of the procedure induces the release 
of macrophage-recruiting chemotoxins that further stimulate 
the secretion of growth factors. Fibroblasts proliferate and 
subsequently deposit type 3 collagen. During the maturation 
phase, balanced production and degradation of the extracel-
lular matrix accompanied by the production of type 1 col-
lagen produce a tissue-strengthening effect.10 These collagen 
deposits can limit filtration.
In bleb development, the remodeling process is continu-
ous, and subconjunctival fibrotic tissue can form early or 
late after surgery. Clinically, this tissue reaction can result 
in an encapsulated or a fibrotic bleb. If the bleb becomes 
encapsulated by tissue, it usually presents as a tense, elevated, 
smooth dome with a thick wall and an aqueous-filled cavity. 
In this situation, the surface area involved in filtration is lim-
ited which may lead to elevated IOP despite the presence of 
the bleb. Encapsulated blebs typically form between 2 and 
6 weeks following traditional filtration surgery and occur in 
8.3%–28% of eyes filtered.11
Subconjunctival fibrosis usually appears clinically as a 
flat bleb and is due to a more aggressive cicatrizing response. 
This can occur postoperatively at any time, although it typi-
cally happens in the first few months after surgery. The bleb 
created by a gel stent has some similarities to trabeculectomy 
blebs, although there are also significant differences. The 
authors of this paper present management strategies specific 
to gel stent blebs.
Bleb failure risk factors
Increased risk of bleb failure is associated with the follow-
ing factors: young age, aphakia, active anterior segment 
neovascularization, conjunctival inflammation, uveitis, 
chronic medication use, previously failed glaucoma filtering 
surgery, and race, among others. The use of topical pros-
taglandins and beta blockers, the most common first-line 
treatments for glaucoma, has also been shown to increase 
the recruitment of inflammatory cells and intensify the 
wound healing cycle.12,13
Preoperative conjunctival optimization
During the preoperative period, it is beneficial to eliminate or 
reduce causes of conjunctival inflammation.14 This involves 
treating ocular surface and lid margin diseases as well as 
reducing toxicity to the conjunctiva from chronic glaucoma 
medication use. This is generally achieved by administering 
topical steroids, reducing or stopping topical IOP-lowering 
medications (replacing them with preservative-free [PF] 
alternatives and/or oral acetazolamide), and using PF lubri-
cants, cyclosporine, or other interventions.5 Depending upon 
the severity of the case, any combination of the above can 
be implemented 1–4 weeks prior to surgery.
intraoperative optimization
Intraoperative factors can also be optimized to reduce the 
risk of fibrosis.5 It is important to ensure that the distal tip 
of the implant is free and mobile (not caught within tenons 
tissue). This facilitates the formation of a diffuse, unrestricted 
bleb. The implant should be positioned ~1 mm in the ante-
rior chamber, 2 mm in the scleral channel, and 3 mm in the 
subconjunctival space to ensure outflow occurs as posterior 
to the limbus as possible. This positioning will also help to 
prevent migration of the implant.5
Pharmacologic agents to modulate the wound healing 
response can also be used at the time of surgery. Differences 
in age, ethnicity, and prior surgical outcomes among patients 
dictate the need for tailoring of the antifibrotic strategy to 
suit the needs of the individual patient.
The use of antimetabolites intraoperatively and post-
operatively in subconjunctival filtering surgeries has been 
reported.15,16 Antimetabolites such as mitomycin C (MMC) 
and 5-fluorouracil (5-FU) have both been successfully used 
to reduce the scarring process.17,18 MMC is an alkylating 
agent that interferes with the cell cycle and induces apoptosis 
of fibroblasts.19 5-FU is an antimetabolite that specifically 
antagonizes various phases of protein synthesis.20 In tradi-
tional filtration surgery, MMC has been found to be more 
effective than 5-FU.21 However, oxidized MMC is inactive 
and requires chemical or enzymatic reductive activation to 
bind to DNA, after which it inhibits DNA replication, mitosis, 
and protein synthesis.22,23 For those cases where MMC does 
not appear to have any effect, this is possibly due to a lack 
of chemical or enzymatic activation. In these instances, the 
use of 5-FU is recommended.
It should be noted that in early studies of the first genera-
tion of the XEN gel stent, no MMC or other antifibrotic agent 
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Failure rates were reduced when MMC was utilized. There 
is growing evidence that injecting MMC at the time of XEN 
implantation and also during needling procedures is becom-
ing the standard of care.25–27 As an alternative, the use of 
5-FU during needling procedures has also been shown to 
be useful.28
Finally, better control of intraoperative bleeding can help 
reduce the secretion of proinflammatory and proangiogenic 
cytokines, improve visibility, and minimize the wound heal-
ing response. Using topical phenylephrine may help with 
vasoconstriction and avoiding subconjunctival and scleral 
vessels may help reduce subconjunctival hemorrhage.
Postoperative wound modulation
Corticosteroids have been traditionally used to stunt fibro-
sis by modifying the inflammatory response following 
glaucoma-filtering surgery, and their use appears to correlate 
with better IOP control.29–32 Although glaucoma patients are 
at heightened risk for a steroid response,33 steroid response 
is less common after filtering surgery.
Prophylactic injections of 0.1 mL of 5-FU (50 mg/mL) to 
the bleb area can be performed during the early postoperative 
period at the slit lamp and have been reported to reduce 
the possibility of more invasive interventions following 
trabeculectomy.34 Some authors recommend doing this 
routinely at week 2 or 3, without waiting for the bleb mor-
phology to change or the IOP to rise. However, the authors 
suggest avoiding prophylactic use of 5-FU in cases where 
IOP is #8 mmHg or in presence of prominent blebs.
Vascular endothelial growth factor (VEGF) plays a role 
in physiological and pathological angiogenesis, and higher 
levels of VEGF are associated with failed glaucoma filtering 
surgeries.35 Therefore, injections of anti-VEGF agents beva-
cizumab and ranibizumab have also been used to modulate 
wound healing. In general, the use of anti-VEGF agents is 
associated with more diffuse blebs with reduced vascularity 
and reduced needling rates.36 However, the use of anti-VEGF 
does not appear to produce a lower IOP when compared to 
the use of MMC.37–39 Overall, anti-VEGF agents have some 
advantages and may be complementary to MMC,40 but have 
yet to establish better results over other antiscarring options 
currently available.
enhancement after implant placement
The XEN stent is currently the only ab interno micro-invasive 
glaucoma surgery (MIGS) capable of being enhanced by 
needling in the postoperative phase. This is in stark contrast 
to the majority of MIGS in which medications are the only 
option when IOPs are not at goal. Needling is a secondary 
procedure intended to free restrictions to aqueous outflow 
due to fibrosis, and it has been shown as an effective way to 
re-establish aqueous flow and lower IOP.41,42 The Preferred 
Practice Patterns published by the American Academy of 
Ophthalmology also include needling as an effective means 
of reviving filtering blebs.43
Bleb appearance and IOP should be factored in the 
decision-making process when considering needling a 
XEN bleb. A high bleb with a hyporeflective wall has 
been described as characteristic of a well-functioning tra-
beculectomy bleb.44 In contrast, a bleb following gel stent 
placement is rather low-lying and diffuse,45–47 and slit lamp 
assessment of improper outflow due to increasing tissue 
resistance can be initially challenging. Therefore, IOP is the 
best parameter to evaluate the need to release fibrosis during 
the surgeons’ learning curve, rather than the bleb appear-
ance. The ideal IOP on postoperative day 1 is between 3 and 
10 mmHg.5 If the IOP is in the high teens or above in the 
early postoperative period, this may represent an implant 
that is imbedded in tenons tissue and surgeons should con-
sider needling (Figure 1).26
When the IOP is elevated, the surgeon should first per-
form gonioscopy to confirm the positioning of the stent, 
Figure 1 Left eye showing a curved implant (caught in tenon) that is visible under 
conjunctiva after stent implantation. iOP is 20 mmHg on four medications (iOP 
21 mmHg after DOC at slit lamp). This is a good candidate to perform needling. 
Courtesy of vanessa vera, MD.
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ensure that it is patent at both ends, verify that the internal 
ostium is not occluded, and rule out retained viscoelastic. 
It is also worthwhile to explore if the patient is manifest-
ing an elevated IOP response to the postoperative steroid 
regimen. In rare cases, YAG laser and/or iridoplasty may 
be performed through a gonioscopy mirror to remove an 
internal ostium obstruction such as pigment, Descemet’s 
membrane, iris, blood, etc. Table 1 lists the factors to 
consider and their influence on the decision to needle the 
XEN bleb.
Timing and technique of needling
The optimal time to perform a needling procedure after the 
XEN gel stent surgery is not well elucidated. In general, nee-
dling occurs in the first 2–3 months after surgery. However, 
if the IOP is not at goal and the bleb area is contracting, bleb 
needling should be considered when the stent can be visual-
ized under the conjunctiva. If and when needling occurs, the 
authors describe three different types of needling:
·	 Type 1: dissection of fibrosis in the subconjunctival-
intratenon space
·	 Type 2: clearance of a fibrotic cap at the external 
implant tip
·	 Type 3: needling of an encapsulated bleb if aqueous sup-
pressant therapy proved unsuccessful (or if preferred, as 
first approach).
Many surgeons find it useful to use a bent needle/blade as 
the angle aids access to the desired site and facilitates rotating 
the cutting edge of the tool. A 27-gauge needle is useful for 
mechanically increasing the bleb area. A 30-gauge needle is 
preferred for fine needling when there is no scarring present 
and the surgeon wants to clear the implant tip. Many surgeons 
also find a 23/24-gauge microvitreoretinal blade particularly 
efficacious as the fine cutting edge can cut away denser scars 
and clear the delicate tip of the stent.
As this paper is a presentation of the authors’ consider-
able experience, they find it helpful to share their individual 
needling techniques.
Table 1 Factors to consider in XEN bleb intervention
Step 1: Measure the intraocular pressure (IOP) Justification for needling
Weaker Stronger
iOP is iOP elevated (irrespective of bleb appearance)? No Yes
iOP vs target is iOP at/below target or above target? At/below target iOP Above target iOP
Change over time is iOP stable or has it increased since last follow-
up?
stable increased 
Step 2: Rule out other causes
steroid response is the patient using steroid medications? Yes (consider steroid 
response if bleb is present)
No
Occlusion of the XEN 
internal ostium
is the anterior chamber end of the implant 
occluded? (gonioscopy)
Yes (consider other rescue 
strategies)
No 
Step 3: Assess the bleb and implant
Bleb appearance 
(slit lamp or optical 
coherence tomography)
is the bleb elevated? Are microcysts present? elevated bleb with microcysts 
present
Low, thick bleb without 
microcysts present
response to digital 
ocular compression 
(DOC)
is it possible to increase the size of the bleb 
following DOC? if so, how easily and to what 
extent?
Bleb size increase over a large 
area in response to modest 
DOC
No bleb size increase in response 
to considerable DOC
Mobility of implant is the tip of the implant still mobile 
(independently of the conjunctival tissue)?
implant freely mobile 
independently of the 
surrounding conjunctiva
Implant fixed within conjunctival/
tenon tissue (Figure 1)
Mobility of the 
conjunctiva 
is the conjunctiva and tenon tissue mobile and 
adjacent to the implant?
Tissues are mobile Tissues are immobile
Bleb patency assessment 
(BPA)
How easily can the contents of the bleb be 
moved posteriorly (using a blunt instrument or 
finger pressure on the eye lid)?
Bleb contents can be easily 
dispersed posteriorly 
Bleb contents cannot easily enter 
surrounding tissue
visibility of the implant is the implant visible beneath the conjunctival 
tissue?
implant obscured by opaque 
overlying tissues – consider 
revision (Figure 2)
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I perform needling at the slit lamp with tetracaine or lidocaine 
hydrochloride ophthalmic gel as a topical anesthesia. It is 
important to avoid subconjunctival hemorrhage, and there-
fore I place a drop of phenylephrine prior to the procedure 
to blanch the vessels. Pressing a tetracaine-soaked cotton tip 
over the area of needling also eliminates pain for the patient. 
Holding the eye open with a lid speculum is not required but 
may be used at the surgeon’s discretion. I generally use my 
third digit to elevate the lid while my index finger and thumb 
hold the needle. Insert a 27-gauge needle 2–3 clock hours 
away from the XEN gel stent site and once the needle reaches 
the implant, gently sweep it above and below the distal end 
of the stent to clear the fibrous attachments. I consider the 
procedure successful if the bleb has a very low elevation and 
the implant is mobile.
If there is no flow of aqueous visible, I may intentionally 
amputate the tip of the stent with my needle. The rational is 
that the implant tip is imbedded in tenons tissue and freeing it 
will allow aqueous to flow. I have also performed YAG laser 
to the internal portion of the XEN if the bleb is not raised after 
needling. If there is no ischemia in the conjunctiva after the 
original XEN implantation, follow needling with an injection 
of 20–40 µg of MMC around the bleb area and/or 0.1 mL of 
5-FU for a total of 5 mg behind the bleb.
I direct the patient to stop use of any topical glaucoma 
medications and prescribe prednisolone acetate and an anti-
biotic for 1 week. I will usually try needling the bleb twice. 
If needling fails twice but I know there is flow through the 
implant, I will perform an open revision. If I cannot detect 
flow through the implant, I will proceed with a tube shunt. 
In a few instances, I have performed a second XEN implant.
Video 1 XEN needling by Arsham Sheybani.
iqbal ike K Ahmed, MD
Prior to needling, I first evaluate the conjunctiva to make 
sure it is healthy. If the conjunctiva is very inflammed, 
I delay needling, cease any agents that may be causing 
inflammation, prescribe a topical corticosteroid, and treat 
any blepharitis.
The day of the needling, I prepare the eye with tetracaine, 
iodopovidone, antibiotics, etc. In patients where 0.4 mg/mL × 
0.1 mL of MMC (40 µg absolute dose) was used at the 
time of surgery, I begin the needling procedure by injecting 
0.5 mg/mL × 0.15 mL of MMC (75 µg absolute dose) into 
the subconjunctiva making sure it covers the distal end of 
the stent. I do not mix it with lidocaine. I use 5-FU if the 
MMC does not seem to be having the desired effect. I may 
use an anti-VEGF agent if the eye is very red at the time of 
needling and repeat later as needed.
At the slit lamp, I use a 27-gauge slit knife (MANI, Inc., 
Tochigi, Japan) bent to make it short, and enter the conjunctiva 
in the adjacent quadrant. I find a lid speculum gets in my way, 
so I ask the patient to look down. I slide the knife under the 
distal end of the stent, swipe it toward the fornix, and then 
repeat the action above the stent. I repeat this motion as needed 
to release fibrosis and allow the XEN gel stent to be positioned 
more anteriorly and superficially. If necessary, I will amputate 
the distal end of the stent. I expect to see the stent free and 
mobile, the bleb raising, and the fibrotic tissue swept away. I 
will inject sodium hyaluronate once I have a bleb.
A surgeon could perform the procedure in the operating 
room initially if uncertain at the slit lamp. I recommend 
needling a bleb when IOP is elevated and the bleb starts 
contracting, but before the bleb is gone; do not miss the 
opportunity. It is important to know which cases should go 
straight to open revision (Figure 2). I will attempt needling 
twice before moving on to another therapeutic option.
Video 2 Xen needling by Iqbal Ike K Ahmed.
ingeborg stalmans, MD
If the conjunctiva is hypervascular, I use subconjunctival 
injections of bevacizumab, topical corticosteroids, and 
preservative-free glaucoma drops days or weeks prior to 
needling. I mostly perform needling in the operating room.
On needling day, I prepare the eye by alternating 3 drops 
of tetracaine, with 2 drops of apraclonidine as a vasoconstric-
tor, and then iodopovidone. My technique for clearing fibrosis 
depends on the type of blockage present. For a clearly visible 
stent without obvious scar, I use a 30-gauge needle. I first 
aim for the tip to see if pulling sub-Tenons away will resume 
aqueous outflow. If not, I very cautiously swipe over and 
under the stent, approaching the stent very closely to open 
up the “sock” around it. The stent can very easily be cut, so 
it is important to use caution.
If the stent tip is free and mobile and slow bleb formation 
is visible, I am satisfied with the needling. Often, I will digi-
tally massage the eye to convincingly see the bleb formation. 
Sometimes, it is possible to see sub-Tenon’s capsule being 
displaced posteriorly.
Video 3 Needling fibrotic bleb after XEN + subconjunc-
tival injection of anti-fibrotics.
If there is a scar around or behind the stent, I use a 
27-gauge vitreoretinal blade to cut through the scar to cre-
ate a new filtering space. For a thick-walled, encapsulated 
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I use a 27-gauge vitreoretinal blade to gently cut the wall of 
the cyst open.
Video 4 Needling an encapsulated bleb after XEN 
gel stent.
After needling, I first inject 0.05 mL of bevacizumab at 
25 mg/mL (total dose 1.25 mg) into the subconjunctiva just 
behind the tip of the stent, followed by 0.1 mL of MMC at 
0.1 mg/mL (total dose 10 µg) posterior to that. My objective 
is to keep the MMC away from the limbus and have the com-
plementary effect of the two antiscarring agents. I also inject 
a subconjunctival steroid depot inferiorly. Postoperatively, 
I have the patient use a topical antibiotic four times a day 
for a few weeks and a topical corticosteroid six times a day 
for 1 month and then slowly taper.
I recommend needling only when the stent is visible, and 
to use meticulous preparation to avoid bleeding. I will gener-
ally perform needling just once, and will perform it twice 
only in exceptional cases. I prefer bleb revision if there is 
thick scar, or inserting a second XEN gel stent if there is no 
visible scar. Lack of scarring indicates that the first implant 
was likely not well placed or not patent. Otherwise, I will 
move on to another filtering surgery.
Dan Lindfield, MD
I personally use two approaches to postoperative bleb 
management: pharmacological bleb modulation with 5-FU 
and/or physical bleb modulation with needling.
I perform pharmacological bleb modulation in all of my 
patients prophylactically. Three weeks after XEN implanta-
tion, I inject 0.1 mL of 50 mg/mL solution of 5-FU (5 mg) 
into the subconjunctiva above the XEN gel stent distal tip. 
I only withhold this step if IOP is #8 mmHg or over draining.
When pharmacological bleb modulation fails, I perform 
physical bleb modulation or needling in the operating room. 
I apply topical adrenaline (1 mg in 1.0 mL) on a cotton swab 
to blanch the area. In cases of primary needling, I use a 
30-gauge long needle to inject 0.1 mL of 5-FU (50 mg/mL); 
in the rare cases that I perform needling a second time, 
I switch to 0.1 mL of 0.2 mg/mL MMC.
I enter the conjunctiva as far away from the stent tip as pos-
sible to minimize potential entry site leak. If the bleb deflates 
through the entry site, it is less likely to function. I then perform 
copious sweeping while trying to avoid hemorrhage. I expect 
to see a slow filling of the bleb area. I suggest new surgeons 
use topical adrenaline and perform needling in the operating 
theater as you will have more control and a better view of the 
implant. Avoid any conjunctival vessels in addition to taking 
care not to perforate the gel stent.
vanessa vera, MD
If I suspect I might need to perform needling, (IOP starts 
creeping up, bleb starts shrinking, conjunctival vascular-
ity is excessive, etc), I start preparing the conjunctiva 
by increasing topical corticosteroids and/or injecting a 
subconjunctival anti-VEGF if vascularity is a concern. 
On the day of the needling, if the conjunctiva is vascular, 
I use 20–40 µg of MMC, injected 10 minutes prior to the 
needling procedure. If the conjunctiva is avascular, I prefer 
to inject 0.1 mL (50 mg/mL) of 5-FU (5 mg) into the bleb 
area after needling is performed.
Figure 2 Photograph A (left) shows the implant visible in the anterior chamber (blue arrow). Photograph B (right) shows the implant visible with difficulty (blue oval) under 
the conjunctiva, iOP of 20 mmHg on three medications. This is a poor candidate for needling. Courtesy of vanessa vera, MD.
































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





I perform needling at the slit lamp using a 27-gauge 
bent needle on an insulin syringe. I ask the patient to look 
down and enter the conjunctiva 2–3 clock hours away from 
the implant. I place my needle bevel halfway under the sub-
conjunctival portion of the implant, not too close to scleral 
exit as it is easy to accidentally cut it, nor at the implant tip. 
I then sweep away from the implant. I go back again, this time 
placing the needle bevel halfway over the stent, and sweep 
away. If I do not see any bleb formation I repeat this, focus-
ing on the area where most resistance was felt. I continue to 
sweep with the needle until the fibrotic tissue is mechani-
cally broken and satisfactory outflow is seen. Ideally, at the 
end of the procedure I will see that the tip of the implant is 
free and mobile from the surrounding tissue and that there 
is low elevation of the conjunctiva. This low elevation can 
make the implant a bit more difficult to visualize compared 
to the pre-needling view (Figure 3). Following the procedure, 
I use the same antibiotic and steroid regimen as after the 
initial surgery.
I avoid entering with the needle in an area that is avascular 
or too close to where the bleb will form. I also avoid sub-
conjunctival hemorrhage, perforating the conjunctiva and/or 
inadvertently cutting the implant (Figure 4). I do amputate 
the distal end of the stent when there is no flow. To do this, 
I place the needle bevel angled over the implant and press 
down against the sclera. I will attempt needing twice, but 
if the bleb fails within a few days of first needling or if too 
much tissue resistance was felt during first needling, then I 
will not needle a second time.
I recommend performing needling only when the stent 
is plainly visible under the conjunctiva, without the aid 
of a laser suture lysis lens or a gonio lens to locate it. If 
you cannot see the stent, then that is not the right patient 
to needle.
Figure 3 Photograph A (right) showing flat bleb and implant (blue oval) under the conjunctiva before needling procedure. Photograph B (left) showing bleb restored with 
mild subconjunctival hemorrhage, air bubbles, and implant (blue oval) after needling procedure. Courtesy of vanessa vera, MD.
Figure 4 Photograph showing inadvertent cut of a gel stent implant (blue arrow) 
































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





There is consensus among all authors that the goal is 
to have the XEN gel stent released from Tenon’s capsule, 
the distal end free and mobile, and a low, diffuse bleb. Nee-
dling should not be performed more than twice, and should 
not be attempted at all if the implant is not clearly visible. 
Achieving an IOP #10 mmHg right after needling (Figure 5) 
may be indicative of good long-term prognosis.5
Just as with the initial surgical procedure, the potential 
risks following needling of the XEN bleb are minimized 
compared to needling a trabeculectomy bleb.28 While pro-
found hypotony, flat chamber, and hyphema are all pos-
sible complications after needling a trabeculectomy bleb, 
they are all very unlikely to happen following needling of 
a XEN bleb.
Alternative options to needling
While needling can be very effective, it is not always suc-
cessful at achieving the desired IOP. When needling has 
been attempted and an acceptable IOP is not achieved and 
sustained, or in cases where the XEN gel stent cannot be 
visualized under the conjunctiva due to a dense and opaque 
layer of tissue, other options should be considered. These 
may include:
·	 Resume IOP-lowering medications. If needling was 
recently performed, consider starting with a preservative-
free aqueous suppressant5 instead of a prostaglandin to 
avoid adding proinflammatory factors (Figure 6).
·	 Perform a bleb revision (open conjunctiva).
·	 Consider converting to a different surgical treatment.
Bleb revision with open conjunctiva
In cases when the implant cannot be visualized under the 
conjunctiva or with poorly functioning encapsulated bleb, 
a bleb revision may be the most appropriate next step. The 
conjunctiva is incised and opened at the limbus spanning 
2–3 clock hours. The posterior conjunctiva is then dissected 
down to the scleral bed and all adhesions that have formed 
between the conjunctiva and the sclera are released. Gentle 
Figure 5 Photograph A (left) shows a stent visible under conjunctiva. iOP was 24 mmHg on two medications after gel stent implantation. subconjunctival injection of 20 µg of 
MMC + needling was performed on slit lamp during that visit (iOP was 8 mmHg right after needling + digital ocular compression). Photograph B (right) shows a bleb present 
with avascular conjunctiva (6 months after needling). iOP was 10 mmHg on no medication. Courtesy of vanessa vera, MD.
Abbreviations: iOP, intraocular pressure; MMC, mitomycin C.
Figure 6 Image showing right eye 6 weeks after XEN gel stent implantation with 
an iOP of 21 mmHg on no medications (preoperatively, iOP was 20 mmHg on 
three medications). The implant is barely visible under the conjunctiva (blue oval). 
The patient is a poor candidate for needling, so the decision was made to resume 
glaucoma medications. At follow-up 26 months after XEN gel stent implantation, 
iOP was 15 mmHg on three medications. Courtesy of vanessa vera, MD.
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cautery is performed to maintain hemostasis. The dissection 
should be performed with caution when approaching the area 
of stent placement through the sclera. Once the implant is 
fully released from the fibrotic tissue, ensure the implant is 
patent and flowing by injecting balanced salt solution (BSS) 
into the anterior chamber (Video 5). Outflow through the 
implant is difficult to visualize as the flow rate may be very 
low; therefore, fluorescein strips may be used along with 
sponges to determine the absence or presence of flow.
Video 5 Bleb revision by Iqbal Ike K Ahmed.
After the stent is fully liberated and flow is confirmed, 
it may still be necessary to perform additional dissection to 
remove adhesions and create a potential space for filtration. 
In some cases, a tenectomy may be necessary to prevent 
future implant fibrosis. The conjunctiva may be closed with 
sutures to ensure a watertight seal. The authors recommend 
an injection of an antifibrotic agent during bleb revision 
surgery (MMC, 5FU, anti-VEGF, and/or corticosteroids).
Conclusion
The key to successful needling include identifying the right 
candidate for intervention and using the appropriate technique. 
Except in cases of encapsulation when aqueous suppressants 
have proven unsuccessful, needling should not be attempted in 
cases where the XEN gel stent is not visible under the conjunc-
tiva. If the stent cannot be visualized, surgeons should consider 
a bleb revision or other interventions, such as restarting topical 
medications or another glaucoma procedure.
If the patient is an appropriate candidate for needling, 
reducing conjunctival inflammation or subconjunctival 
hemorrhage can help improve the chances for success. 
An inflamed conjunctiva should be treated pre-emptively. 
The use of antimetabolites and other antifibrotic agents 
are associated with greater needling success rates, and the 
authors encourage their use. Freeing the XEN implant from 
Tenon’s tissue and elevating a bleb is the goal of needling. 
After needling, there should be a reduction in IOP confirm-
ing improved outflow.
The suggested approaches to bleb management following 
implantation of the XEN gel stent are based on published 
best practices in ophthalmology and the collective, consider-
able experience of the authors. This information is meant to 
complement, not replace formal training with the XEN gel 
stent, and should always be applied to an individual patient 
at the surgeon’s discretion.
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